Skip to main content

Market Overview

Benzinga's M&A Chatter for Wednesday January 8, 2014

Benzinga's M&A Chatter for Wednesday January 8, 2014

The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday January 8, 2014:

Forest Laboratories to Acquire Aptalis for $2.9 Billion in Cash

The Deal:
After being rumored late Tuesday, Forest Laboratories (NYSE: FRX) announced on Wednesday that it has reached an agreement to acquire specialty gastrointestinal and cystic fibrosis company Aptalis, for $2.9 billion in cash from shareholders, which include PE firm TPG.

The deal is expected to close in H1 2014.

Forest Labs closed Wednesday at $69.30, a gain of 18%.

Dunkin Shares Rise on Report of Interest from Chinese Buyer

The Rumor:
Shares of Dunkin Brands (NASDAQ: DNKN) surged higher Wednesday, on a report from Global Times that Chinese food chain Goubuli is looking to acquire a U.S. coffee chain, though the company did not reveal the name of the coffee chain.

There was no indication that Dunkin Brands was aware of the report.

Dunkin Brands closed Wednesday at $47.52, a gain of 1.73%.

Riverbed Receives $19/Share Bid from Elliott Management

The Offer:
Shares of Riverbed Technology (NASDAQ: RVBD) spiked higher Wednesday, as investor Elliot Management offered to acquire all outstanding shares of Riverbed for $19.00 per share in cash. Elliott currently owns 10.5% of Riverbed shares.

Riverbed's Board said it will review the offer and communicate its views in due course.

Riverbed Technology closed Wednesday at $19.53, a gain of 9.5%.


Related Articles (FRX + DNKN)

View Comments and Join the Discussion!

Posted-In: M&A News Rumors Hedge Funds Insider Trades General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at